Clinical trial
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
NCT00406172 · Asociación para Evitar la Ceguera en México, Other · Withdrawn
Key facts
| NCT number | NCT00406172 |
|---|---|
| Title | Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) |
| Official title | Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) |
| Lead sponsor | Asociación para Evitar la Ceguera en México, Other |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystoid Macular Edema |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 0 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Dec 4, 2006 |
| Last update posted | Jun 5, 2024 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: